PharmaEssentia USA Corporation, a subsidiary of Taiwan-based PharmaEssentia Corp. (TPEx: 6446), a global biopharmaceutical innovator leveraging deep expertise and proven scientific principles to deliver new biologics in haematology and oncology, announced the resubmission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA), seeking approval for ropeginterferon alfa-2b-njft for the treatment of polycythemia vera (PV), a rare blood cancer. Source- PharmaEssentia Corp.
The Polycythemia vera (PV) market insight report provides a comprehensive insight on patient segmentation based on age, sex, symptoms (Spleen pain, Weight loss, Fever, Bone pain, Night sweats, Pruritus and Fatigue) Stages (Stage I, II, III & IV) has been provided into the epidemiology (Incidence and Prevalence) section of the Polycythemia vera and its treatment in the 8 MM countries, covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, and China
The incidence diagnosed cases of Polycythemia vera (PV) is ~1.75 to 2.27 cases per 100,000 population of men and approximately 1.52 per 100,000 population of women in the USA. The prevalence of Polycythemia vera (PV) is ~19 to 26 cases per 100,000 population. The average age at which PV is diagnosed is 55 to 65 years. It is uncommon in individuals younger than 30 years.
In terms of pharmacologic therapies, some key assets are under different phases of development such as; Ropeginterferon alfa-2b; PharmaEssentia Corporation, Idasanutlin; Roche Holding AG, KRT-232; KartosTherapeutics, Inc, PTG-300; Protagonist Therapeutics, Inc., Pegasys; Roche Holding AG, Givinostat; Italfarmaco S.p.A. PTG -300 is an injectable hepcidin mimetic in clinical development for the potential treatment of beta-thalassemia and polycythemia vera. Hepcidin is a natural peptide hormone that regulates iron absorption and utilization in the body through sequestration and release from tissue macrophages and intestinal enterocytes.
Thelansis is specialized in pharmaceutical market research and market Insight Report Company, published reports across the therapeutic area which includes both rare / ultra-rare and mainstream indication. Over the period of time, we have built a strong repository of 6,000+ Bio-pharma reports which essentially covers Epidemiology study and Market forecasting based on the KOL opinions. Competitive intelligence and track of trial results throughout the phases of development executed by a team of a mix of Scientific and Business backgrounds. As an organization, the major focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making.
Medulloblastoma – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030
Chordoma – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030
Myelofibrosis – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030
Adenoid cystic carcinoma (ACC) –Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030
Burkitt Lymphoma – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030
Gurugram- Onework Gold Souk mall, Phase I, Sector 43, Haryana-122002, India Contact no.: +91(124) 404-1731 Sales office 183-Asylum Street Hartford, CT-06103, USA USA +1 (267) 244-6955, Email email@example.com, firstname.lastname@example.org
Menafn, Reportedtimes, PR-Wirein, iCN Internal Distribution, Research Newswire, English